Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

medRxiv(2022)10.1101/2022.03.21.22272544Source: DataRank Database

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 0.208. It has been cited 3 times.

N/A

0.208DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: greenTopics (17)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.208

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (55)

Karine Alcala ORCID,Elham Khodayari Moez ORCID,Florence Guida ORCID,Sera Thomas ORCID,Hana Zahed ORCID

Live enrichment

PubMed:19022398 OpenAlex:https://openalex.org/W4220951070

National Institutes of Health

Grant: 1R03CA245979-01A1

Evaluating risk prediction models for use in lung cancer screening in diverse populations around the world

National Institutes of Health

Grant: 5R01CA097193-02

Physicians Health Study II: Prevention Trial of Vitamins

National Institutes of Health

Grant: 3P30CA047904-07S1

CANCER CENTER SUPPORT GRANT

National Institutes of Health

Grant: 5U01AG018033-03

GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT

National Institutes of Health

Grant: 5R01CA251758-04

Addressing racial disparities in lung cancer screening

National Institutes of Health

Grant: 5R01CA040360-15

PHYSICIANS HEALTH STUDY--CONTINUED FOLLOW UP

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5U19CA203654-04

Integrative analysis of lung cancer etiology and risk

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

National Institutes of Health

Grant: 3P50CA090440-08S1

SPORE in Lung Cancer

National Institutes of Health

Grant: 5R01HL034595-02

A RANDOMIZED TRIAL OF ASPIRIN AND MORTALITY IN US MDS

National Institutes of Health

Grant: 5U01CA086308-05

CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS

National Institutes of Health

Grant: 1U01CA202979-01

Southern Community Cohort Study

greenLicense: cc-by-nc-nd

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2022/03/22/2022.03.21.22272544.full.pdf

repositoryhttps://doi.org/10.1101/2022.03.21.22272544

Fields of Study

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsRadiomics and Machine Learning in Medical Imaging03 medical and health sciences0302 clinical medicine

Keywords

Lung cancerMedicineBiomarkerMalignancyNodule (geology)OncologyCancerInternal medicineCohortEtiologyCohort studyBiology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Reduced inequalities